- Home
- VERU vs MRSN Comparison
VERU vs MRSN Comparison
Compare VERU & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- MRSN
- Stock Information
- Founded
- VERU 1971
- MRSN 2001
- Country
- VERU United States
- MRSN United States
- Employees
- VERU N/A
- MRSN N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- MRSN Health Care
- Exchange
- VERU Nasdaq
- MRSN Nasdaq
- Market Cap
- VERU 54.6M
- MRSN 47.1M
- IPO Year
- VERU 1990
- MRSN 2017
- Fundamental
- Price
- VERU $3.75
- MRSN $10.23
- Analyst Decision
- VERU Strong Buy
- MRSN Strong Buy
- Analyst Count
- VERU 3
- MRSN 3
- Target Price
- VERU $33.33
- MRSN $33.00
- AVG Volume (30 Days)
- VERU 139.0K
- MRSN 69.1K
- Earning Date
- VERU 12-15-2025
- MRSN 11-12-2025
- Dividend Yield
- VERU N/A
- MRSN N/A
- EPS Growth
- VERU N/A
- MRSN N/A
- EPS
- VERU N/A
- MRSN N/A
- Revenue
- VERU $16,886,419.00
- MRSN $34,769,000.00
- Revenue This Year
- VERU N/A
- MRSN N/A
- Revenue Next Year
- VERU N/A
- MRSN N/A
- P/E Ratio
- VERU N/A
- MRSN N/A
- Revenue Growth
- VERU 337.24
- MRSN 16.14
- 52 Week Low
- VERU $2.64
- MRSN $5.21
- 52 Week High
- VERU $14.20
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- VERU 47.71
- MRSN 62.25
- Support Level
- VERU $3.61
- MRSN $8.76
- Resistance Level
- VERU $3.99
- MRSN $10.64
- Average True Range (ATR)
- VERU 0.30
- MRSN 0.78
- MACD
- VERU -0.10
- MRSN -0.03
- Stochastic Oscillator
- VERU 14.52
- MRSN 64.32
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.